Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients.

Abstract

PURPOSE:

To study a commonly used Astragalus-based herbal formula previously found effective in non-small cell lung cancer (NSCLC) on the pharmacokinetics of docetaxel in patients with NSCLC.

METHODS:

Patients with advanced NSCLC who progressed after prior platinum-containing chemotherapy were accrued and received docetaxel at 35 mg/m(2) for 3 weeks followed by 1 week of rest. At 4 days prior to the second dosing, Jinfukang was given orally. Pharmacokinetic studies of initial-dose docetaxel (in the absence of Jinfukang) and the third dose (in the presence of Jinfukang) were compared.

RESULTS:

Of the 24 patients enrolled, 21 started Jinfukang and docetaxel. Jinfukang had no significant impact on the pharmacokinetics of docetaxel. Median time to progression or withdrawal from treatment was 7 weeks. Twelve patients were removed from study for progression of disease; nine patients withdrew.

CONCLUSIONS:

Jinfukang did not alter the pharmacokinetics of docetaxel nor appear to affect survival in this study.

• Authors: Barrie R Cassileth, Naiyer Rizvi, Gary Deng, K Simon Yeung, Andrew Vickers, Stacey Guillen, Derek Woo, Marci Coleton, Mark G Kris
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 65 Issue 1 Pg. 67-71 (Dec 2009) ISSN: 1432-0843 [Electronic] Germany
• PMID: 19421753 (Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Drugs, Chinese Herbal
• Plant Extracts
• Taxoids
• jinfukang
• Docetaxel

Topics

• Administration, Oral
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (adverse effects, pharmacokinetics, therapeutic use)
• Astragalus propinquus (chemistry)
• Carcinoma, Non-Small-Cell Lung (drug therapy, mortality)
• Disease Progression
• Docetaxel
• Drug Interactions
• Drugs, Chinese Herbal (adverse effects, pharmacokinetics, therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Lung Neoplasms (drug therapy, mortality)
• Male
• Middle Aged
• Plant Extracts (pharmacology)
• Survival Rate
• Taxoids (adverse effects, pharmacokinetics, therapeutic use)